An orange rod-shaped bacterium with blue flagella.

The cell membrane is bacteria's first line of defense against antibiotics.

Credit: istock/luismmolina

A potential new target for developing antibiotics

A new understanding of one enzyme’s role in assembling a key macromolecule in the bacterial cell wall takes a step toward overcoming antibiotic resistance. 
| 3 min read
Register for free to listen to this article
Listen with Speechify
0:00
3:00

Approximately five million deaths in 2019 were associated with antibiotic resistant bacteria according to a 2022 Lancet  report (1). To fight resistance, scientists are seeking new ways to make these superbugs easier to kill. One strategy is to target the bacterial cell membrane, which plays an important role in developing antibiotic resistance due to its direct interaction with drugs. 

In a recent study published in Nature, structural biologist Filippo Mancia and his team at Columbia University analyzed the structure of an enzyme ligase called WaaL that transfers O-antigen sugars to the bacterial lipid core during the formation of lipopolysaccharide (LPS) (2). In gram-negative bacteria, lipopolysaccharides (LPS) are made out of a lipid and sugar chain.   This macromolecule resides in the bacterial membrane and is one of its greatest defenses against antibiotics. 

“The membrane protein is the first thing that a drug sees. It is responsible for how the cell responds to extracellular stimuli,” said Mancia. 

While scientists knew that LPS protects gram-negative bacteria from foreign invaders, how the molecule forms remained a mystery. Understanding the steps that produce LPS could help researchers develop drugs that interrupt this process, making bacterial cells more vulnerable to attack.

A picture of the authors of the Nature paper. From left to right, Filippo Mancia, Khuram Ashraf, and Rie Nygaard.
Filippo Mancia, Khuram Ashraf, and Rie Nygaard studied the role of O-antigen ligase in the formation of bacterial lipopolysaccharide.
CREDIT: FILIPPO MANCIA

To investigate the structure of WaaL, Mancia’s team turned to cryogenic electron microscopy (CryoEM) and antigen-binding fragment (Fab) technology. Unlike methods that measure X-ray diffractions, CryoEM does not require crystallizing the protein, which can be challenging. Instead, they froze the proteins and analyzed them close to their native conditions. Still, “WaaL is a very complex protein and has several transmembrane helices that go through the membrane, which makes it much harder to work with,” said Stephen Trent, a molecular microbiologist at the University of Georgia and coauthor of the study.

To find a stable form of WaaL that would be easier to study, the researchers screened 200 unique bacterial sources. They identified Cupriavidus metallidurans, a gram-negative bacterium that has adapted to survive environments with high concentrations of heavy metals and isolated its WaaL to image with CryoEM. 

By combining their high-resolution CryoEM images with molecular dynamics simulations and biochemical assays, the researchers deciphered the steps leading to sugar transfer. During this enzymatic reaction, the lipid carrier undecaprenyl pyrophosphate (UndPP) carries the O-antigen sugars and forms a complex structure with WaaL. The lipid A olligosaccharide then binds to a separate binding site on the WaaL enzyme where the O-antigen is subsequently transferred from the UndPP. Finally, the UndPP detaches from the mature, fully formed LPS consisting of O-antigen-linked-lipid A oligosaccharide.  

This finding revealed a critical role for WaaL in catalyzing the final step of LPS synthesis and identified the enzyme as a promising drug target for weakening the bacterial cell membrane.

According to Trent, this knowledge has important implications for drug development. The LPS is “like the armor that protects the cell,” he said. “Anything you can do to disrupt that armor makes them more susceptible.” 

On gram-negative bacteria, LPS is critical for resistance to antibiotics that attack their outer structures such as beta-lactams like penicillin. A WaaL inhibitor could prevent a bacterial cell from making the correct LPS structure and allow antibiotics or the immune system to attack it more easily, Trent explained. 

The researchers’ use of CryoEM to investigate the formation of LPS is “very clever,” said Yaoqin Hong, a molecular microbiologist at Queensland University of Technology who was not involved in the study. Hong would be interested to learn if the effects of inhibiting WaaL are reversible. “There are definitely ways to extend from this work to understand how [bacterial cell walls] are regulated,” he said. 

References 

  1. Murray C.J.L., Ikuta, K.S., Sharara, F. et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet  390629-655 (2022). https://doi.org/10.1016/S0140-6736(21)02724-0
  2. Ashraf, K.U., Nygaard, R., Vickery, O.N. et al. Structural basis of lipopolysaccharide maturation by the O-antigen ligase. Nature  604, 371–376 (2022). https://doi.org/10.1038/s41586-022-04555-x 

About the Author

  • Kristel Tjandra is a science journalism intern at Drug Discovery News and a postdoctoral fellow at Stanford University studying multidrug-resistant bacteria.

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A scientist wearing gloves handles a pipette over a petri dish and a color-coded microplate in a laboratory setting.

The unsung tools behind analytical testing success

Learn how fundamental laboratory tools like pipettes and balances support analytical precision.
A 3D rendering of motor neurons lit up with blue, purple, orange, and green coloring showing synapses against a black background.

Improving ALS research with pluripotent stem cell-derived models 

Discover new advancements in modeling amyotrophic lateral sclerosis.

Automating 3D cell selection

Discover precise automated tools for organoid and spheroid handling. 
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue